Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases
- 27 August 2009
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (3) , 371-378
Abstract
This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC). The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w. Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047). Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.Keywords
This publication has 31 references indexed in Scilit:
- Effect of bisphosphonates on pain and quality of life in patients with bone metastasesNature Reviews Clinical Oncology, 2009
- Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with RadiationCancer Research, 2007
- Renal Cell Carcinoma GuidelineEuropean Urology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- TGF-β Promotes the Establishment of Renal Cell Carcinoma Bone MetastasisJournal of Bone and Mineral Research, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a reviewAnnals of Oncology, 2006
- Raf: A Strategic Target for Therapeutic Development Against CancerJournal of Clinical Oncology, 2005
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood, 2003
- Renal cell carcinomaCurrent Opinion in Oncology, 2001